Advertisement
Drug Pipeline
Subscribe to Drug Pipeline
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Big Step in Battling Bladder Disease

October 16, 2014 1:33 pm | News | Comments

Novel device that stays in the bladder and slowly releases drugs sells to pharmaceutical giant. Read more...                                                             

Personalized Cellular Therapy Achieves Remission in Leukemia Patients

October 16, 2014 12:36 pm | News | Comments

Ninety percent of children and adults with ALL who had relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy, CTL019, developed at the Perelman School of Medicine at the University of Pennsylvania. Read more...

Roche, Cardiorentis AG Collaborate on AHF Drug Safety

October 16, 2014 10:41 am | News | Comments

Cardiorentis AG, a privately held biopharmaceutical company, announced a collaboration with Roche to establish the therapeutic efficacy and safety of Ularitide, the company's investigational drug for acute heart failure (AHF). Read more...

Advertisement

FDA Approves Boehringer Ingelheim's Drug for Lung Disease

October 16, 2014 10:30 am | News | Comments

 Boehringer Ingelheim announced that the FDA approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). Read more...

Eisai's Thyroid Cancer Drug Gets FDA Priority Review

October 15, 2014 10:45 am | News | Comments

Eisai Inc. announced that the FDA has accepted for review the NDA for its in-house developed agent lenvatinib mesylate as a treatment for progressive RAI-refractory DTC and granted the NDA Priority Review status. Read more...

Selecta, JDRF, Sanofi Collaborate on SVP Immunotherapy for Type 1

October 15, 2014 10:31 am | News | Comments

Selecta Biosciences and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop an SVP immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. Read more...

Medtronic Begins Study of First Predictive Low Glucose Management Technology

October 14, 2014 1:39 pm | News | Comments

Medtronic Inc. announced that the first patients have been enrolled in an investigational device exemption (IDE) study of its breakthrough Predictive Low Glucose Management (PLGM) technology, marking a critical step toward development of an artificial pancreas in the U.S. market. Read more...

Rats of New York and The Diseases They Carry

October 14, 2014 12:29 pm | News | Comments

In the first study to look at would-be diseases carried by New York City rats, scientists at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health identified bacterial pathogens, including E. coli, Salmonella, and C. difficile, that cause mild to life-threatening gastroenteritis in people. Read more...

Advertisement

Biologists Find Gene That Could Stop Tumors in Their Tracks

October 14, 2014 12:21 pm | News | Comments

The dirt in your backyard may hold the key to isolating cancerous tumors and to potential new treatments for a host of cancers. Read more...                                         

Astellas Collaborates with Harvard for Retinal Degeneration Treatment

October 14, 2014 12:13 pm | News | Comments

Astellas Pharma Inc. announced a research collaboration with an investigator at Harvard focused on discovering the pathologic mechanism for retinitis pigmentosa and identification of new therapeutic targets. Read more...

Rare Genetic Disease Protects Against Bipolar Disorder

October 14, 2014 12:01 pm | News | Comments

A team of scientists led by researchers at the UMass Medical School and UMMSM have identified what is likely a key genetic pathway underlying bipolar disorder, a breakthrough that could lead to better drugs for treating bipolar affective disorder, as well as depression and other related mood disorders. Read more...

C3BS Enrolls Patients in Switzerland in its Phase 3 Clinical Trial Chart-1

October 14, 2014 10:39 am | News | Comments

C3BS, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announced it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase 3 trial for C-Cure in Switzerland. Read more...

Chemical Derived from Broccoli Sprouts Shows Promise in Treating Autism

October 14, 2014 10:27 am | News | Comments

Results of a small clinical trial suggest that a chemical derived from broccoli sprouts — and best known for claims that it can help prevent certain cancers — may ease classic behavioral symptoms in those with autism spectrum disorders (ASDs). Read more...

Advertisement

Researchers Treat Pulmonary Hypertension Through the Leaves of Plants

October 14, 2014 10:18 am | News | Comments

Researchers at the University of Pennsylvania and the University of Florida have identified a drug that can be used to treat pulmonary hypertension, a disease for which few therapy options exist. Read more...                            

Scientists Link ALS Progression to Increased Protein Instability

October 14, 2014 10:09 am | News | Comments

A new study by scientists from The Scripps Research Institute (TSRI), Lawrence Berkeley National Laboratory (Berkeley Lab) and other institutions suggests a cause of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Read more...

New Cancer Drug to Begin Trials in Multiple Myeloma Patients

October 13, 2014 3:11 pm | News | Comments

Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year. Read more...                            

Greater Rates of Mitochondrial Mutations in Children Born to Older Mothers

October 13, 2014 2:54 pm | News | Comments

The discovery of a "maternal age effect" by a team of Penn State scientists that could be used to predict the accumulation of mitochondrial DNA mutations in maternal egg cells -- and the transmission of these mutations to children -- could provide valuable insights for genetic counseling. Read more... 

BMS, Pharmacyclics and Janssen Collaborate on Non-Hodgkin Lymphoma Drug

October 13, 2014 2:25 pm | News | Comments

Bristol-Myers Squibb Company, Pharmacyclics Inc., and Janssen Research & Development LLC announced they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in combination with Imbruvica. Read more...

Scientists Characterize a New Tumor Syndrome

October 13, 2014 11:08 am | News | Comments

Scientists at the Luxembourg Center for Systems Biomedicine (LCSB) of the University of Luxembourg have published their findings that mutations in a gene known as “ARMC5” promote the growth of benign tumors in the adrenal glands and on the meninges: ARMC5 appears to belong to the group of so-called tumour suppressor gene. Read more...

Concert Pharmaceuticals' Spasticity Drug Gets Positive Reviews

October 13, 2014 10:54 am | News | Comments

Concert Pharmaceuticals Inc. announced Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity. Read more...                        

Phase 2 Study to Evaluate Hepatitis C Drug Combination

October 13, 2014 10:41 am | News | Comments

Medivir AB announced that its partner Janssen recently initiated patient enrolment in a phase 2 study called IMPACT. This study evaluates the efficacy, safety and pharmacokinetics of the NS3/4A protease inhibitor simeprevir administered once daily in combination with Gilead’s nucleotide inhibitor sofosbuvir and Bristol-Myers Squibb’s (BMS) NS5A replication complex inhibitor daclatasvir. Read more...

FDA Approves Drug for Chemo-Associated Nausea, Vomiting

October 13, 2014 10:10 am | News | Comments

Helsinn Group and Eisai Inc. announced that the FDA approved Akynzeo for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy Read more...                

Researchers Begin Study of Ebola Vaccine in Africa

October 10, 2014 2:06 pm | News | Comments

The first study of a possible Ebola vaccine is underway in Africa: University of Maryland researchers say three health care workers in Mali received the experimental shots. Read more...

Giant Step Toward New Diabetes Treatment

October 10, 2014 9:55 am | News | Comments

Harvard stem cell researchers announced that they have made a giant leap forward in the quest to find a truly effective treatment for type 1 diabetes, a condition that affects an estimated 3 million Americans at a cost of about $15 billion annually Read more...

Canadian Ebola Vaccine to Be Shipped to Geneva Next Week, WHO Said

October 10, 2014 9:35 am | by Helen Branswell, The Canadian Press | News | Comments

Experimental Ebola vaccine that Canada has donated to the World Health Organization will be shipped to Geneva next week, the global health agency said. Read more...                                   

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading